Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-human cytomegalovirus monoclonal antibody combination CSJ-148

A combination agent composed of two human monoclonal antibodies against the human cytomegalovirus (HCMV), LJP538 and LJP539, with potential immunomodulating activity. Upon administration of CSJ-148, both LJP538 and LJP539 bind to and inhibit the function of viral HCMV glycoproteins that are essential for HCMV infection; LJP538 targets and binds to glycoprotein B (gB) and LJP539 targets and inhibits the pentameric complex, consisting of glycoproteins gH, gL, UL128, UL130, and UL131. Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:antiviral agent CSJ148
HCMV neutralizing human mAb combination CSJ-148
Code name:CSJ 148
CSJ-148
CSJ148
LJP538 and LJP539
LJP538 plus LJP539
LJP538/LJP539
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search